全文获取类型
收费全文 | 12633篇 |
免费 | 1122篇 |
国内免费 | 127篇 |
出版年
2023年 | 54篇 |
2022年 | 51篇 |
2021年 | 232篇 |
2020年 | 158篇 |
2019年 | 196篇 |
2018年 | 211篇 |
2017年 | 173篇 |
2016年 | 360篇 |
2015年 | 604篇 |
2014年 | 657篇 |
2013年 | 795篇 |
2012年 | 950篇 |
2011年 | 902篇 |
2010年 | 568篇 |
2009年 | 467篇 |
2008年 | 701篇 |
2007年 | 601篇 |
2006年 | 607篇 |
2005年 | 567篇 |
2004年 | 500篇 |
2003年 | 502篇 |
2002年 | 469篇 |
2001年 | 192篇 |
2000年 | 188篇 |
1999年 | 171篇 |
1998年 | 119篇 |
1997年 | 110篇 |
1996年 | 73篇 |
1995年 | 83篇 |
1994年 | 105篇 |
1993年 | 98篇 |
1992年 | 145篇 |
1991年 | 116篇 |
1990年 | 99篇 |
1989年 | 105篇 |
1988年 | 98篇 |
1987年 | 80篇 |
1986年 | 70篇 |
1985年 | 71篇 |
1984年 | 119篇 |
1983年 | 75篇 |
1982年 | 87篇 |
1981年 | 89篇 |
1980年 | 81篇 |
1979年 | 71篇 |
1978年 | 92篇 |
1977年 | 73篇 |
1976年 | 58篇 |
1975年 | 58篇 |
1973年 | 56篇 |
排序方式: 共有10000条查询结果,搜索用时 196 毫秒
1.
Xinzhu Deng David Michaelson Jason Tchieu Jin Cheng Diana Rothenstein Regina Feldman Sang-gyu Lee John Fuller Adriana Haimovitz-Friedman Lorenz Studer Simon Powell Zvi Fuks E. Jane Albert Hubbard Richard Kolesnick 《PloS one》2015,10(6)
Mammalian NOTCH1-4 receptors are all associated with human malignancy, although exact roles remain enigmatic. Here we employ glp-1(ar202), a temperature-sensitive gain-of-function C. elegans NOTCH mutant, to delineate NOTCH-driven tumor responses to radiotherapy. At ≤20°C, glp-1(ar202) is wild-type, whereas at 25°C it forms a germline stem cell⁄progenitor cell tumor reminiscent of human cancer. We identify a NOTCH tumor phenotype in which all tumor cells traffic rapidly to G2⁄M post-irradiation, attempt to repair DNA strand breaks exclusively via homology-driven repair, and when this fails die by mitotic death. Homology-driven repair inactivation is dramatically radiosensitizing. We show that these concepts translate directly to human cancer models. 相似文献
2.
3.
Detection of a Novel Unglycosylated Form of Hepatitis C Virus E2 Envelope Protein That Is Located in the Cytosol and Interacts with PKR 总被引:2,自引:0,他引:2 下载免费PDF全文
The hepatitis C virus (HCV) envelope protein E2 has been shown to accumulate in the lumen of the endoplasmic reticulum (ER) as a properly folded glycoprotein as well as large aggregates of misfolded proteins. In the present study, we have identified an additional unglycosylated species, with an apparent molecular mass of 38 kDa (E2-p38). In contrast to the glycosylated E2, E2-p38 is significantly less stable and is degraded through the proteasome pathway. Correspondingly, E2-p38 is found to be ubiquitinated. E2-p38 is localized mostly in the cytosol, in contrast to the glycosylated form, which is exclusively membrane associated. Alpha interferon (IFN-alpha) treatment or overexpression of the double-stranded RNA-activated protein kinase (PKR) significantly increased the stability of E2-p38, consistent with a previous report (D. R. Taylor, S. T. Shi, P. R. Romano, G. N. Barber, and M. M. Lai, Science 285:107-110, 1999) that E2 interacts with PKR and inhibits its kinase activity. Direct interaction between PKR and E2-p38, but not the glycosylated form of E2, was also observed. These results show that E2-p38 is the form of E2 that interacts with PKR in the cytosol and may contribute to the resistance of HCV to IFN-alpha. Thus, an ER protein can exist in the cytosol as an unglycosylated species and impair cellular functions. 相似文献
4.
5.
Leo Lap-Yan Wong Ian Pak-Yan Lam Tracy Yuk-Nar Wong Wai-Lung Lai Heong-Fai Liu Lam-Lung Yeung Yick-Pang Ching 《PloS one》2013,8(7)
Hepatocellular carcinoma (HCC) is one of the major malignancies worldwide and is associated with poor prognosis due to the high incidences of metastasis and tumor recurrence. Our previous study showed that overexpression of p21-activated protein kinase 1 (PAK1) is frequently observed in HCC and is associated with a more aggressive tumor behavior, suggesting that PAK1 is a potential therapeutic target in HCC. In the current study, an allosteric small molecule PAK1 inhibitor, IPA-3, was evaluated for the potential in suppressing hepatocarcinogenesis. Consistent with other reports, inhibition of PAK1 activity was observed in several human HCC cell lines treated with various dosages of IPA-3. Using cell proliferation, colony formation and BrdU incorporation assays, we demonstrated that IPA-3 treatment significantly inhibited the growth of HCC cells. The mechanisms through which IPA-3 treatment suppresses HCC cell growth are enhancement of apoptosis and blockage of activation of NF-κB. Furthermore, our data suggested that IPA-3 not only inhibits the HCC cell growth, but also suppresses the metastatic potential of HCC cells. Nude mouse xenograft assay demonstrated that IPA-3 treatment significantly reduced the tumor growth rate and decreased tumor volume, indicating that IPA-3 can suppress the in vivo tumor growth of HCC cells. Taken together, our demonstration of the potential preclinical efficacy of IPA-3 in HCC provides the rationale for cancer therapy. 相似文献
6.
7.
8.
9.
10.